Organon has begun a deal to sell its JADA system to Laborie Medical in a transaction valued at up to $465 million.

JADA is a medical device that uses a low-level intrauterine vacuum to control and treat abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Organon acquired JADA in June 2021 and has since built a team that positions Laborie to expand the product’s reach and value.

About 100 employees are expected to transfer to Laborie as part of the agreement.

“I am incredibly proud of the work the JADA team and Organon have done to help more than 136,000 new mothers in over 20 countries, positioning JADA as a recognized standard of care in postpartum hemorrhage (PPH) management,” said Organon interim CEO Joseph Morrissey. “This transaction puts JADA in the hands of Laborie, a leading medical technology innovator with an established history in maternal health, that is well-positioned to further expand access to JADA for the benefit of mothers globally. It is also another step towards improving capacity in Organon’s balance sheet to be able to pursue other growth opportunities in women’s health biopharma in the future.”

RELATED: FDA OKs Organon’s JADA System to Control Postpartum Hemorrhage

The up to $465 million transaction value represents 6.5 times JADA’s trailing 12-months revenues, reflective of its successful launch and U.S. expansion over the past four years. The transaction was approved by Organon’s board and is expected to close in Q1 2026.

“Childbirth is one of the most personal and profound moments in a woman’s life, and every mother deserves to feel supported throughout it. The JADA System helps care teams provide treatment when it matters most and being part of that mission is something we hold with deep pride and purpose at Laborie,” said Chris Smith, president and CEO of Laborie. “We’re equally inspired by the dedication and strength of the commercial team behind JADA and are excited to have them join Laborie to help strengthen our leading performance in the OB segment.”